Articles with public access mandates - Sandrine DegryseLearn more
Available somewhere: 10
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
S Peirs, F Matthijssens, S Goossens, I Van de Walle, K Ruggero, ...
Blood, The Journal of the American Society of Hematology 124 (25), 3738-3747, 2014
Mandates: Research Foundation (Flanders), UK Medical Research Council, Wellcome Trust …
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia
C Vicente, C Schwab, M Broux, E Geerdens, S Degryse, S Demeyer, ...
Haematologica 100 (10), 1301, 2015
Mandates: Research Foundation (Flanders), European Commission
JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model
S Degryse, CE De Bock, L Cox, S Demeyer, O Gielen, N Mentens, ...
Blood, The Journal of the American Society of Hematology 124 (20), 3092-3100, 2014
Mandates: Research Foundation (Flanders), European Commission
HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development
CE de Bock, S Demeyer, S Degryse, D Verbeke, B Sweron, O Gielen, ...
Cancer discovery 8 (5), 616-631, 2018
Mandates: Research Foundation (Flanders), European Commission
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
S Degryse, CE De Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke, ...
Leukemia 32 (3), 788-800, 2018
Mandates: Research Foundation (Flanders), European Commission
Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors
A Dagklis, S Demeyer, J De Bie, E Radaelli, D Pauwels, S Degryse, ...
Blood, The Journal of the American Society of Hematology 128 (23), 2642-2654, 2016
Mandates: Research Foundation (Flanders), European Commission
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
S Degryse, J Cools
Journal of hematology & oncology 8, 1-5, 2015
Mandates: Research Foundation (Flanders)
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL
S Degryse, S Bornschein, CE de Bock, E Leroy, M Vanden Bempt, ...
Blood, The Journal of the American Society of Hematology 131 (4), 421-425, 2018
Mandates: Research Foundation (Flanders)
Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma
AJ Luginbuhl, JM Johnson, LA Harshyne, AJ Linnenbach, SK Shukla, ...
Clinical Cancer Research 28 (5), 915-927, 2022
Mandates: US National Institutes of Health
Blood First Edition Paper, prepublished online September 5, 2014; DOI 10.1182/blood-2014-04-566687
S Degryse, CE de Bock, L Cox, S Demeyer, O Gielen, N Mentens, ...
Mandates: Research Foundation (Flanders), European Commission
Publication and funding information is determined automatically by a computer program